| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Soyasapogenol B targets multiple cellular pathways involved in cancer, inflammation, and metabolism. It inhibits proliferation of Hep-G2 cells and triggers endoplasmic reticulum stress response, mediating apoptosis and autophagy in colorectal cancer. The compound has hypocholesterolemic, anticomplementary, and hepatoprotective effects. It has biofunctions in cell signaling, membrane integrity, and fuel and energy storage. Its mechanism involves modulation of cell signaling and stress response pathways.
|
|---|---|
| ln Vitro |
In vitro, Soyasapogenol B inhibits proliferation of cultured Hep-G2 cells. It triggers endoplasmic reticulum stress response, mediating apoptosis and autophagy in colorectal cancer. The compound exhibits anticancer, hypocholesterolemic, anticomplementary, and hepatoprotective effects. It has biofunctions in cell signaling, membrane integrity, and fuel and energy storage. Its activities have been characterized in various cell-based assays using cancer cell lines and hepatocytes.
|
| ln Vivo |
In vivo, Soyasapogenol B has demonstrated hepatoprotective activity on hepatotoxicity. It has anticancer, hypocholesterolemic, and anticomplementary effects. The compound is a natural triterpenoid found in soybeans. Its hepatoprotective effects have been demonstrated in animal models of liver injury. Further in vivo studies are ongoing to fully characterize its therapeutic potential. The compound is typically administered orally or via injection in preclinical studies.
|
| Enzyme Assay |
Soyasapogenol B enzyme assays involve measuring its effects on cancer cell proliferation and apoptosis. Cell proliferation is assessed by MTT or CCK-8 assays in Hep-G2 and colorectal cancer cell lines. Apoptosis is evaluated by Annexin V/PI staining and caspase activity assays. Endoplasmic reticulum stress is assessed by measuring ER stress markers such as CHOP and GRP78. Anticomplementary activity is assessed by measuring complement inhibition. Hypocholesterolemic activity is assessed by measuring cholesterol levels. Assays are performed in appropriate buffer systems with positive controls.
|
| Cell Assay |
Soyasapogenol B cell-based assays are conducted in Hep-G2 cells, colorectal cancer cells, and other cell lines. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with the compound at varying concentrations. Cell viability is assessed by MTT or CCK-8 assays. Apoptosis is evaluated by Annexin V/PI staining and caspase activity assays. Autophagy is assessed by measuring LC3-II conversion and autophagosome formation. Endoplasmic reticulum stress markers are measured by Western blot. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
Soyasapogenol B in vivo studies are conducted in animal models of cancer and liver injury. Tumor-bearing mice are treated with Soyasapogenol B via oral administration or injection. Tumor growth is monitored by caliper measurements. Apoptosis and autophagy in tumors are assessed by TUNEL assay and immunohistochemistry. For hepatoprotection studies, animal models of liver injury are used and liver enzymes are measured. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biomarker analysis at study endpoints. Studies are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
Soyasapogenol B (MW 458.72 g/mol, C30H50O3) is a pentacyclic oleanane-type triterpenoid. It is a constituent of soybean saponins. The compound is soluble in DMSO and other organic solvents. It is stable under recommended storage conditions. Soyasapogenol B has anticancer, hypocholesterolemic, anticomplementary, and hepatoprotective effects. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution would be determined in species-specific studies.
|
| Toxicity/Toxicokinetics |
Soyasapogenol B is generally well-tolerated in preclinical studies. The compound is a natural triterpenoid from soybeans with established safety profiles. Its anticancer, hepatoprotective, and hypocholesterolemic effects have been demonstrated with acceptable safety profiles. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References |
|
| Additional Infomation |
Soyasapogenol B is a pentacyclic triterpenoid compound belonging to the oleanane type. It contains a double bond between positions 12 and 13, with hydroxyl groups at positions 3β, 22β, and 24. It is derived from the hydride of oleanane. Soyasapogenol B has been reported in soybeans, Streptomyces, and several other organisms with relevant data. See also: Red clover flowers (partial); Alfalfa whole plant (partial).
Soyasapogenol B is a pentacyclic oleanane-type triterpenoid aglycone derived from soyasaponins, found in soybeans and legumes. It exhibits anticancer (inhibits Hep-G2 proliferation), hypocholesterolemic, anticomplementary, and hepatoprotective effects. The compound triggers ER stress response, mediating apoptosis and autophagy in colorectal cancer. It has biofunctions in cell signaling, membrane integrity, and energy storage. All applications are limited to non-human research use. |
| Molecular Formula |
C30H50O3
|
|---|---|
| Molecular Weight |
458.7162
|
| Exact Mass |
458.376
|
| CAS # |
595-15-3
|
| PubChem CID |
115012
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
555.5±50.0 °C at 760 mmHg
|
| Melting Point |
258 - 259 °C
|
| Flash Point |
226.6±24.7 °C
|
| Vapour Pressure |
0.0±3.4 mmHg at 25°C
|
| Index of Refraction |
1.562
|
| LogP |
7.41
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
33
|
| Complexity |
848
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@]12CC[C@@H]([C@]([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(C[C@H]5O)(C)C)C)C)C)(C)CO)O
|
| InChi Key |
YOQAQNKGFOLRGT-UXXABWCISA-N
|
| InChi Code |
InChI=1S/C30H50O3/c1-25(2)16-20-19-8-9-22-27(4)12-11-23(32)28(5,18-31)21(27)10-13-30(22,7)29(19,6)15-14-26(20,3)24(33)17-25/h8,20-24,31-33H,9-18H2,1-7H3/t20-,21+,22+,23-,24+,26+,27-,28+,29+,30+/m0/s1
|
| Chemical Name |
(3S,4S,4aR,6aR,6bS,8aR,9R,12aS,14aR,14bR)-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-3,9-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~109.00 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.45 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1800 mL | 10.8999 mL | 21.7998 mL | |
| 5 mM | 0.4360 mL | 2.1800 mL | 4.3600 mL | |
| 10 mM | 0.2180 mL | 1.0900 mL | 2.1800 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
